News

The potential banner lineup for Genshin Impact 5.8 may have leaked, highlighting a Nod-Krai character and anticipated ...
In phase 1, 75% of patients had also received chemotherapy whereas only 31% had in phase 2. In the phase 1 portion of the trial, ARV-110 doses ranged from 35–700 mg QD or 210–420 mg BID. Based on ...
As of February 28, 2025, 99 patients were enrolled (Phase 1a, n=8; Phase 1b, n=6, Phase 2, n=30, 25, and 30 in Cohorts A, B, and C, respectively). The baseline characteristics are summarized below: ...